Tags: Drug.

JNJ-Q2 is a broad-spectrum fluoroquinolone antibacterial drug being developed for the treatment of acute bacterial skin and skin-structure infections and community-acquired pneumonia. Specifically JNJ-Q2 is being actively studied for treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections.Furiex Pharmaceuticals has licensed JNJ-Q2 from Janssen Pharmaceutica a unit of Johnson & Johnson which discovered JNJ-Q2.

JNJ-Q2.svg
IUPAC name
7-[(3E)-3-(2-Amino-1-fluoroethylidene)-1-piperidinyl]-1-cyclopropyl-6-fluoro-14-dihydro-8-methoxy-4-oxo-3-quinolinecarboxylic acid

Loading...

This page contains content from the copyrighted Wikipedia article "JNJ-Q2"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.